ES2890226T3 - Compuestos de benzodiazolio como inhibidores del ENaC - Google Patents
Compuestos de benzodiazolio como inhibidores del ENaC Download PDFInfo
- Publication number
- ES2890226T3 ES2890226T3 ES17807900T ES17807900T ES2890226T3 ES 2890226 T3 ES2890226 T3 ES 2890226T3 ES 17807900 T ES17807900 T ES 17807900T ES 17807900 T ES17807900 T ES 17807900T ES 2890226 T3 ES2890226 T3 ES 2890226T3
- Authority
- ES
- Spain
- Prior art keywords
- methyl
- ethyl
- amino
- pyrrolo
- general formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 **(C=C1)C=Cc2c1[n](*)c(CNC(c1nc(c(*)c(*)[n]3)c3nc1N)=O)[n+]2* Chemical compound **(C=C1)C=Cc2c1[n](*)c(CNC(c1nc(c(*)c(*)[n]3)c3nc1N)=O)[n+]2* 0.000 description 19
- CRCZPRHYWDKNBB-UHFFFAOYSA-N C=C(C(F)(F)F)O Chemical compound C=C(C(F)(F)F)O CRCZPRHYWDKNBB-UHFFFAOYSA-N 0.000 description 2
- ZYQDUZXGRVKQIH-XBXGWEOASA-N CC(C)(C)OC(N(C)CCCN(C[C@@H]([C@H]([C@@H]1OC(c2ccccc2)OC[C@H]1O)O)O)C[C@@H]([C@H]([C@@H]1OC(c2ccccc2)OC[C@H]1O)O)O)=O Chemical compound CC(C)(C)OC(N(C)CCCN(C[C@@H]([C@H]([C@@H]1OC(c2ccccc2)OC[C@H]1O)O)O)C[C@@H]([C@H]([C@@H]1OC(c2ccccc2)OC[C@H]1O)O)O)=O ZYQDUZXGRVKQIH-XBXGWEOASA-N 0.000 description 1
- UBRZVFBAPAUSBV-UHFFFAOYSA-N CC(C)(C)OC(NCCCNC(OCC1c(cccc2)c2-c2ccccc12)=O)=O Chemical compound CC(C)(C)OC(NCCCNC(OCC1c(cccc2)c2-c2ccccc12)=O)=O UBRZVFBAPAUSBV-UHFFFAOYSA-N 0.000 description 1
- NXAKRVADEMLOPT-UHFFFAOYSA-N CC(C)(C)OC(NCCN(CC1)CCC1N)=O Chemical compound CC(C)(C)OC(NCCN(CC1)CCC1N)=O NXAKRVADEMLOPT-UHFFFAOYSA-N 0.000 description 1
- ZPPQQEDMNHNPGD-INIZCTEOSA-N CC(C)(C)OC(NCC[C@@H](C(N)=O)NCCCNC(OCc1ccccc1)=O)=O Chemical compound CC(C)(C)OC(NCC[C@@H](C(N)=O)NCCCNC(OCc1ccccc1)=O)=O ZPPQQEDMNHNPGD-INIZCTEOSA-N 0.000 description 1
- YWPCTUISODBHNP-UHFFFAOYSA-N CC(C)(C)OC(NCCc(cc1)ccc1-c1ccc(CC#N)cc1)=O Chemical compound CC(C)(C)OC(NCCc(cc1)ccc1-c1ccc(CC#N)cc1)=O YWPCTUISODBHNP-UHFFFAOYSA-N 0.000 description 1
- AOMKVPKFNNEPLP-UHFFFAOYSA-N CCC(C1)=C(CNC(c2nc(cc[nH]3)c3nc2N)=O)N(CC)c2c1ccc(Cl)c2 Chemical compound CCC(C1)=C(CNC(c2nc(cc[nH]3)c3nc2N)=O)N(CC)c2c1ccc(Cl)c2 AOMKVPKFNNEPLP-UHFFFAOYSA-N 0.000 description 1
- CXVJPMIBHJWFPN-JZXLJBGVSA-N CCCC(c(cc(cc1)OCCCN(C[C@@H]([C@H]([C@@H]2OC(c3ccccc3)OC[C@H]2O)O)O)C[C@@H]([C@H]([C@@H]2OC(c3ccccc3)OC[C@H]2O)O)O)c1N(CC)C(CN)=C)=O Chemical compound CCCC(c(cc(cc1)OCCCN(C[C@@H]([C@H]([C@@H]2OC(c3ccccc3)OC[C@H]2O)O)O)C[C@@H]([C@H]([C@@H]2OC(c3ccccc3)OC[C@H]2O)O)O)c1N(CC)C(CN)=C)=O CXVJPMIBHJWFPN-JZXLJBGVSA-N 0.000 description 1
- KTARMXVUARLDBL-UHFFFAOYSA-N CCCCc1c(CNC(c2c(N)nc3[nH]ccc3n2)=O)[n](CC)c2c1ccc(OCCN)c2 Chemical compound CCCCc1c(CNC(c2c(N)nc3[nH]ccc3n2)=O)[n](CC)c2c1ccc(OCCN)c2 KTARMXVUARLDBL-UHFFFAOYSA-N 0.000 description 1
- KJNAQLAYFMMSMJ-UHFFFAOYSA-N CCN1c(ccc(C(N(CC2)CCC2NC(OC(C)(C)C)=O)=O)c2)c2N(CC)C1CNC(C1=Nc(cc[nH]2)c2NC1(C)N)=O Chemical compound CCN1c(ccc(C(N(CC2)CCC2NC(OC(C)(C)C)=O)=O)c2)c2N(CC)C1CNC(C1=Nc(cc[nH]2)c2NC1(C)N)=O KJNAQLAYFMMSMJ-UHFFFAOYSA-N 0.000 description 1
- FXSJFDQFYUXDQP-UHFFFAOYSA-N CC[n]1c(cc(C(F)(F)F)cc2)c2p(C)c1CN Chemical compound CC[n]1c(cc(C(F)(F)F)cc2)c2p(C)c1CN FXSJFDQFYUXDQP-UHFFFAOYSA-N 0.000 description 1
- JCIQSPAVEYBSJO-UHFFFAOYSA-N CC[n]1c(cc(C(F)(F)F)cc2)c2p(C)c1CNC(OC(C)(C)C)=O Chemical compound CC[n]1c(cc(C(F)(F)F)cc2)c2p(C)c1CNC(OC(C)(C)C)=O JCIQSPAVEYBSJO-UHFFFAOYSA-N 0.000 description 1
- CASUFGHKZFMHIT-UHFFFAOYSA-N CC[n]1c(cc(CCCNC(OC(C)(C)C)=O)cc2)c2nc1CN(C(c1c2cccc1)=O)C2=O Chemical compound CC[n]1c(cc(CCCNC(OC(C)(C)C)=O)cc2)c2nc1CN(C(c1c2cccc1)=O)C2=O CASUFGHKZFMHIT-UHFFFAOYSA-N 0.000 description 1
- AAIWSCWUTBAKAF-UHFFFAOYSA-N CC[n]1c(cc(cc2)Br)c2nc1CN(C(c1c2cccc1)=O)C2=O Chemical compound CC[n]1c(cc(cc2)Br)c2nc1CN(C(c1c2cccc1)=O)C2=O AAIWSCWUTBAKAF-UHFFFAOYSA-N 0.000 description 1
- IBWHEQHMFNRQLM-UHFFFAOYSA-N CC[n]1c(cc(cc2)C(O)=O)c2nc1CN Chemical compound CC[n]1c(cc(cc2)C(O)=O)c2nc1CN IBWHEQHMFNRQLM-UHFFFAOYSA-N 0.000 description 1
- VOUBXLRKWXTZFC-UHFFFAOYSA-N CC[n]1c(cc(cc2)C(OC(C)(C)C)=O)c2nc1CNC(OCc1ccccc1)=O Chemical compound CC[n]1c(cc(cc2)C(OC(C)(C)C)=O)c2nc1CNC(OCc1ccccc1)=O VOUBXLRKWXTZFC-UHFFFAOYSA-N 0.000 description 1
- HIOHBJKERHRYKK-UHFFFAOYSA-N CC[n]1c(cc(cc2)C(OC)=O)c2nc1CNC(OC(C)(C)C)=O Chemical compound CC[n]1c(cc(cc2)C(OC)=O)c2nc1CNC(OC(C)(C)C)=O HIOHBJKERHRYKK-UHFFFAOYSA-N 0.000 description 1
- RPVPQFODRFKIPA-UHFFFAOYSA-N CC[n]1c(cc(cc2)Cl)c2nc1CN(C(c1c2cccc1)=O)C2=O Chemical compound CC[n]1c(cc(cc2)Cl)c2nc1CN(C(c1c2cccc1)=O)C2=O RPVPQFODRFKIPA-UHFFFAOYSA-N 0.000 description 1
- VJLXYMINFIWXJV-UHFFFAOYSA-N CC[n]1c(cc(cc2)OCCCNC(OC(C)(C)C)=O)c2nc1CNC(OCC1c2ccccc2-c2ccccc12)=O Chemical compound CC[n]1c(cc(cc2)OCCCNC(OC(C)(C)C)=O)c2nc1CNC(OCC1c2ccccc2-c2ccccc12)=O VJLXYMINFIWXJV-UHFFFAOYSA-N 0.000 description 1
- CDUYWLCYIYTGCX-UHFFFAOYSA-N COC(c(nc12)c(N)nc1[n](COCC[Si+](C)(C)C)cc2C#N)=O Chemical compound COC(c(nc12)c(N)nc1[n](COCC[Si+](C)(C)C)cc2C#N)=O CDUYWLCYIYTGCX-UHFFFAOYSA-N 0.000 description 1
- KKDUEQBKFRCXSH-UHFFFAOYSA-N NCC(CC1)CCN1C(OCC1c2ccccc2-c2c1cccc2)=O Chemical compound NCC(CC1)CCN1C(OCC1c2ccccc2-c2c1cccc2)=O KKDUEQBKFRCXSH-UHFFFAOYSA-N 0.000 description 1
- UMUSQTRXUQXFQA-QFPCDXEJSA-N NCCCN(C[C@@H]([C@H]([C@@H]1OC(c2ccccc2)OC[C@H]1O)O)O)C[C@@H]([C@H]([C@@H]1OC(c2ccccc2)OC[C@H]1O)O)O Chemical compound NCCCN(C[C@@H]([C@H]([C@@H]1OC(c2ccccc2)OC[C@H]1O)O)O)C[C@@H]([C@H]([C@@H]1OC(c2ccccc2)OC[C@H]1O)O)O UMUSQTRXUQXFQA-QFPCDXEJSA-N 0.000 description 1
- RNVLKSOXBSATJW-GASCZTMLSA-N N[C@H](CC1)CC[C@H]1NC(OCC1c2ccccc2-c2c1cccc2)=O Chemical compound N[C@H](CC1)CC[C@H]1NC(OCC1c2ccccc2-c2c1cccc2)=O RNVLKSOXBSATJW-GASCZTMLSA-N 0.000 description 1
- YENVPXQJWFSSRK-UHFFFAOYSA-N Nc1nc([nH]cc2)c2nc1C([n]1cncc1)=O Chemical compound Nc1nc([nH]cc2)c2nc1C([n]1cncc1)=O YENVPXQJWFSSRK-UHFFFAOYSA-N 0.000 description 1
- DHFDZHZHURSLDI-UHFFFAOYSA-N O=C(NC1CCNCC1)OCC1c2ccccc2-c2ccccc12 Chemical compound O=C(NC1CCNCC1)OCC1c2ccccc2-c2ccccc12 DHFDZHZHURSLDI-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N OC(C(F)(F)F)=O Chemical compound OC(C(F)(F)F)=O DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- JJEWLCLLKVXSFI-AJEQDSBPSA-N O[C@@H](CN(CCOCCOCCOCCNC(OCC1c(cccc2)c2-c2c1cccc2)=O)C[C@@H]([C@H]([C@@H]1OC(c2ccccc2)OC[C@H]1O)O)O)[C@H]([C@@H]1OC(c2ccccc2)OC[C@H]1O)O Chemical compound O[C@@H](CN(CCOCCOCCOCCNC(OCC1c(cccc2)c2-c2c1cccc2)=O)C[C@@H]([C@H]([C@@H]1OC(c2ccccc2)OC[C@H]1O)O)O)[C@H]([C@@H]1OC(c2ccccc2)OC[C@H]1O)O JJEWLCLLKVXSFI-AJEQDSBPSA-N 0.000 description 1
- KMUSIARGJMDKPC-KFWFLNGKSA-N O[C@@H](CN(C[C@@H]([C@H]([C@@H]1OC(c2ccccc2)OC[C@H]1O)O)O)C1CCNCC1)[C@H]([C@@H]1OC(c2ccccc2)OC[C@H]1O)O Chemical compound O[C@@H](CN(C[C@@H]([C@H]([C@@H]1OC(c2ccccc2)OC[C@H]1O)O)O)C1CCNCC1)[C@H]([C@@H]1OC(c2ccccc2)OC[C@H]1O)O KMUSIARGJMDKPC-KFWFLNGKSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1619694.1A GB201619694D0 (en) | 2016-11-22 | 2016-11-22 | Compounds |
| PCT/GB2017/053499 WO2018096325A1 (en) | 2016-11-22 | 2017-11-22 | Benzodiazolium compounds as enac inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2890226T3 true ES2890226T3 (es) | 2022-01-18 |
Family
ID=57993838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17807900T Active ES2890226T3 (es) | 2016-11-22 | 2017-11-22 | Compuestos de benzodiazolio como inhibidores del ENaC |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US10941149B2 (https=) |
| EP (1) | EP3544981B1 (https=) |
| JP (1) | JP6980014B2 (https=) |
| KR (1) | KR102517273B1 (https=) |
| CN (1) | CN110214141B (https=) |
| AU (1) | AU2017364308B2 (https=) |
| CA (1) | CA3043132A1 (https=) |
| DK (1) | DK3544981T3 (https=) |
| EA (1) | EA039607B1 (https=) |
| ES (1) | ES2890226T3 (https=) |
| GB (1) | GB201619694D0 (https=) |
| HU (1) | HUE055692T2 (https=) |
| IL (1) | IL266745B (https=) |
| MA (1) | MA46878A (https=) |
| MX (1) | MX389496B (https=) |
| PL (1) | PL3544981T3 (https=) |
| PT (1) | PT3544981T (https=) |
| TW (1) | TWI756305B (https=) |
| WO (1) | WO2018096325A1 (https=) |
| ZA (1) | ZA201902710B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201610854D0 (en) | 2016-06-21 | 2016-08-03 | Entpr Therapeutics Ltd | Compounds |
| GB201619694D0 (en) | 2016-11-22 | 2017-01-04 | Entpr Therapeutics Ltd | Compounds |
| GB201717051D0 (en) * | 2017-10-17 | 2017-11-29 | Enterprise Therapeutics Ltd | Compounds |
| GB201801355D0 (en) | 2018-01-26 | 2018-03-14 | Enterprise Therapeutics Ltd | Compounds |
| GB201808093D0 (en) * | 2018-05-18 | 2018-07-04 | Enterprise Therapeutics Ltd | Compounds |
| GB201908453D0 (en) | 2019-06-12 | 2019-07-24 | Enterprise Therapeutics Ltd | Compounds for treating respiratory disease |
| CR20220006A (es) | 2019-06-12 | 2022-06-06 | Tmem16A Ltd | Compuestos para tratar enfermedad respiratoria |
| GB201910608D0 (en) | 2019-07-24 | 2019-09-04 | Enterprise Therapeutics Ltd | Compounds |
| EP4259607A1 (en) * | 2020-12-11 | 2023-10-18 | Tmem16A Limited | Benzimidazole derivatives for treating respiratory disease |
| CN118852442A (zh) | 2023-04-26 | 2024-10-29 | 上海麦科思生物医药有限公司 | 抗ptk7抗体及其用途 |
| GB202406247D0 (en) | 2024-05-03 | 2024-06-19 | Enterprise Therapeutics Ltd | Compounds and pharmaceutical compositions |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6858615B2 (en) | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenyl guanidine sodium channel blockers |
| US6858614B2 (en) | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenolic guanidine sodium channel blockers |
| US6903105B2 (en) | 2003-02-19 | 2005-06-07 | Parion Sciences, Inc. | Sodium channel blockers |
| US20050090505A1 (en) | 2003-08-18 | 2005-04-28 | Johnson Michael R. | Methods of reducing risk of infection from pathogens |
| AU2004266704B2 (en) | 2003-08-18 | 2012-02-23 | Parion Sciences, Inc. | Capped pyrazinoylguanidine sodium channel blockers |
| US7375107B2 (en) | 2003-08-18 | 2008-05-20 | Parion Sciences, Inc. | Alaphatic pyrazinoylguanidine sodium channel blockers |
| JP2007502829A (ja) | 2003-08-18 | 2007-02-15 | パリオン・サイエンシィズ・インコーポレーテッド | 環状ピラジノイルグアニジンナトリウムチャネルブロッカー |
| US7745442B2 (en) | 2003-08-20 | 2010-06-29 | Parion Sciences, Inc. | Methods of reducing risk of infection from pathogens |
| AU2004285053B2 (en) | 2003-10-28 | 2010-10-21 | Vertex Pharmaceuticals, Incorporated | Benzimidazoles useful as modulators of ion channels |
| US7399766B2 (en) | 2004-08-18 | 2008-07-15 | Parion Sciences, Inc. | Soluble amide & ester pyrazinoylguanidine sodium channel blockers |
| US20060223849A1 (en) * | 2005-03-14 | 2006-10-05 | Mjalli Adnan M | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors |
| US7807834B2 (en) | 2005-08-03 | 2010-10-05 | Parion Sciences, Inc. | Capped pyrazinoylguanidine sodium channel blockers |
| GB0526244D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| GB0526240D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| US8288391B2 (en) | 2007-04-03 | 2012-10-16 | Parion Sciences, Inc. | Pyrazinoylguanidine compounds for use as taste modulators |
| CN101687851B (zh) | 2007-05-07 | 2013-02-27 | 诺瓦提斯公司 | 有机化合物 |
| WO2009019506A1 (en) | 2007-08-03 | 2009-02-12 | Astrazeneca Ab | Heterocyclyc sulfonamides having edg-1 antagonistic activity |
| CL2008003651A1 (es) | 2007-12-10 | 2009-06-19 | Novartis Ag | Compuestos derivados de 3,5-diamino-6-cloropirazinamida sustituida; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una condición inflamatoria o alergica, en particular una enfermedad inflamatoria u obstructiva de las vias respiratorias. |
| WO2009139948A1 (en) | 2008-02-26 | 2009-11-19 | Johnson Michael R | Poly aromatic sodium channel blockers |
| AU2009248179A1 (en) | 2008-05-13 | 2009-11-19 | Novartis Ag | 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid derivatives and their use as epithelial sodium channel blockers for the treatment of arway diseases |
| CA2727196A1 (en) | 2008-06-10 | 2009-12-17 | Novartis Ag | Organic compounds |
| WO2011028740A1 (en) | 2009-09-03 | 2011-03-10 | Glaxo Group Limited | ENaC BLOCKERS |
| WO2011079087A1 (en) | 2009-12-23 | 2011-06-30 | Glaxo Group Limited | Enac blockers |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| TW201204353A (en) * | 2010-06-08 | 2012-02-01 | Vertex Pharma | Formulations of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
| US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
| AR086745A1 (es) | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida |
| WO2013064450A1 (en) | 2011-11-02 | 2013-05-10 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof |
| US8859559B2 (en) | 2011-12-20 | 2014-10-14 | Boehringer Ingelheim International Gmbh | Substituted pyrazines and their use in the treatment of disease |
| MX2014014648A (es) | 2012-05-29 | 2015-09-04 | Parion Sciences Inc | Aminoamidas tipo dendrimero que poseen actividad bloqueadora del canal de sodio para el tratamiento de ojo reseco y otras enfermedades mucosas. |
| WO2014044849A1 (en) | 2012-09-24 | 2014-03-27 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof |
| SG10201708931XA (en) | 2012-12-17 | 2017-12-28 | Parion Sciences Inc | Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration |
| RU2018138195A (ru) | 2012-12-17 | 2018-12-18 | Пэрион Сайенсиз, Инк. | Соединения 3,5-диамино-6-хлор-n-(n-(4- фенилбутил)карбамимидоил)пиразин-2-карбоксамида |
| ES2674665T3 (es) | 2012-12-17 | 2018-07-03 | Parion Sciences, Inc. | Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida |
| WO2014177469A1 (en) | 2013-04-30 | 2014-11-06 | Boehringer Ingelheim International Gmbh,M | Diaminopyrazine compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof |
| US9656972B2 (en) | 2013-07-02 | 2017-05-23 | The California Institute For Biomedical Research | Compounds for treatment of cystic fibrosis |
| JP6449870B2 (ja) | 2013-07-08 | 2019-01-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 肺および気道の疾患を処置するための上皮性ナトリウムチャネルの阻害剤としてのアミロライド型化合物 |
| EP3022196B1 (en) | 2013-07-15 | 2017-09-06 | Boehringer Ingelheim International GmbH | Novel benzimidazolium compounds |
| EP3022197B1 (en) | 2013-07-15 | 2017-09-06 | Boehringer Ingelheim International GmbH | Novel tetra- and pentasubstituted benzimidazolium compounds |
| EP3022198B1 (en) | 2013-07-15 | 2019-09-11 | Boehringer Ingelheim International GmbH | Novel 5-substituted benzimidazolium compounds |
| JP6449880B2 (ja) | 2013-08-08 | 2019-01-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ピラジンアミド化合物 |
| JP6667538B2 (ja) | 2015-01-12 | 2020-03-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器系疾患の治療に有用な置換ベンズイミダゾリウム化合物 |
| JP6671378B2 (ja) * | 2015-01-12 | 2020-03-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器系疾患の治療に有用な置換ベンズイミダゾリウム化合物 |
| EP3245202B1 (en) | 2015-01-12 | 2020-03-11 | Boehringer Ingelheim International GmbH | Tetrasubstituted benzimidazolium compounds useful in the treatment of respiratory diseases |
| US9981954B2 (en) | 2015-01-12 | 2018-05-29 | Boehringer Ingelheim International Gmbh | 2-(pyrazin-2-ylcarbonylaminomethyl) benzimidazolium compounds as epithelial sodium channel inhibitors |
| CA2996087A1 (en) | 2015-08-20 | 2017-02-23 | Boehringer Ingelheim International Gmbh | Annelated phenoxyacetamides |
| BR112018002115A2 (pt) | 2015-08-20 | 2018-09-18 | Boehringer Ingelheim Int | benzamidas aneladas |
| GB201610854D0 (en) * | 2016-06-21 | 2016-08-03 | Entpr Therapeutics Ltd | Compounds |
| GB201619694D0 (en) * | 2016-11-22 | 2017-01-04 | Entpr Therapeutics Ltd | Compounds |
-
2016
- 2016-11-22 GB GBGB1619694.1A patent/GB201619694D0/en not_active Ceased
-
2017
- 2017-11-22 PT PT178079000T patent/PT3544981T/pt unknown
- 2017-11-22 TW TW106140573A patent/TWI756305B/zh active
- 2017-11-22 AU AU2017364308A patent/AU2017364308B2/en active Active
- 2017-11-22 KR KR1020197016141A patent/KR102517273B1/ko active Active
- 2017-11-22 WO PCT/GB2017/053499 patent/WO2018096325A1/en not_active Ceased
- 2017-11-22 ES ES17807900T patent/ES2890226T3/es active Active
- 2017-11-22 JP JP2019527365A patent/JP6980014B2/ja active Active
- 2017-11-22 CA CA3043132A patent/CA3043132A1/en active Pending
- 2017-11-22 CN CN201780084165.3A patent/CN110214141B/zh active Active
- 2017-11-22 PL PL17807900T patent/PL3544981T3/pl unknown
- 2017-11-22 MA MA046878A patent/MA46878A/fr unknown
- 2017-11-22 MX MX2019005934A patent/MX389496B/es unknown
- 2017-11-22 EP EP17807900.0A patent/EP3544981B1/en active Active
- 2017-11-22 US US16/462,794 patent/US10941149B2/en active Active
- 2017-11-22 DK DK17807900.0T patent/DK3544981T3/da active
- 2017-11-22 HU HUE17807900A patent/HUE055692T2/hu unknown
- 2017-11-22 EA EA201991253A patent/EA039607B1/ru unknown
-
2019
- 2019-04-30 ZA ZA2019/02710A patent/ZA201902710B/en unknown
- 2019-05-20 IL IL266745A patent/IL266745B/en unknown
-
2020
- 2020-11-24 US US17/103,559 patent/US11739094B2/en active Active
-
2023
- 2023-06-30 US US18/345,840 patent/US12371436B2/en active Active
-
2025
- 2025-06-11 US US19/235,076 patent/US20250304590A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2890226T3 (es) | Compuestos de benzodiazolio como inhibidores del ENaC | |
| EP3794002B1 (en) | Compounds | |
| CN103649089B (zh) | 作为pi3k抑制剂的吡咯并三嗪酮 | |
| EP3472154B1 (en) | Compounds | |
| MX2015004327A (es) | Derivados de pirrolotriazinona como inhibidores de pi3k. | |
| TW201446767A (zh) | 作為磷脂肌醇3-激酶抑製劑之吡咯並三嗪衍生物 | |
| EP3697788B1 (en) | Bis(pentahydroxyhexyl)amino substituted 2-{[(3-amino-pyrazin-2-yl)formamido]methyl}-1h-1,3-benzodiazol-3-ium derivatives as enac inhibitors for treating respiratory diseases | |
| BR112019009864B1 (pt) | Compostos de benzodiazolínio, composição farmacêutica e produto compreendendo os referidos compostos, seus processos de fabricação e uso | |
| HK40014276A (en) | Benzodiazolium compounds as enac inhibitors | |
| HK40014276B (en) | Benzodiazolium compounds as enac inhibitors |